Advancing capsid engineering: improving tropism and delivery efficiency of AAV

Cell & Gene Therapy Insights 2024; 10(5), 267–272

DOI: 10.18609/cgti.2024.040

Published: 26 March
Li Ou

Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks to Li Ou, Vice President of Research, Avirmax, Inc., exploring innovative approaches in next-­generation AAV capsid engineering. Addressing critical challenges, they discuss hurdles posed by the limited delivery efficiency of AAV capsids in addition to the ongoing battle of addressing lingering vector immunogenicity issues.